PELP1 and breast carcinoma: For example, the upregulation of Proline-, glutamic acid-and leucine-rich protein1 (PELP1), an oestrogen receptor coactivator and proto-oncogene, has been reported to be associated with poor prognosis in breast cancer patients (Habashy et al., 2010), and with resistance to endocrine therapy in vitro (Flågeng et al., 2015).